← Eichor
Study identifier: NCT05079399 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Biomarker of Diabetic Retinopathy

Condition: Diabetic Retinopathy  ·  Sponsor: Indiana University

PhaseN/A
Planned participants192
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the oxygen/nutrient deficiency. Ultimately affecting the normal vision. There is no known marker that will provide information on the health status of retinal blood vessels. Using highly specialized cells in the blood, this study will try to discover a marker of DR.

This description comes directly from the study's public registry record.

Talk to the study team

Ashay D Bhatwadekar, PhD, RPh  ·  3172785075  ·  abhatwad@iupui.edu

Amir R Hajrasouliha, MD  ·  3179441154  ·  amhajras@iu.edu

Always discuss trial participation with your own doctor first.

Locations (3)

Spring Mill ClinicCarmel, Indiana, United StatesRecruiting
Eskenazi Eye ClinicIndianapolis, Indiana, United StatesRecruiting
Glick Eye InstituteIndianapolis, Indiana, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05079399